000 | 01959 a2200625 4500 | ||
---|---|---|---|
005 | 20250518034459.0 | ||
264 | 0 | _c20191220 | |
008 | 201912s 0 0 eng d | ||
022 | _a2374-4243 | ||
024 | 7 |
_a10.1080/23744235.2019.1595709 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aHesstvedt, Liv | |
245 | 0 | 0 |
_aThe impact of age on risk assessment, therapeutic practice and outcome in candidemia. _h[electronic resource] |
260 |
_bInfectious diseases (London, England) _c06 2019 |
||
300 |
_a425-434 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Observational Study | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAge Factors |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAged, 80 and over |
650 | 0 | 4 |
_aAntifungal Agents _xtherapeutic use |
650 | 0 | 4 |
_aCandidemia _xdrug therapy |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aIncidence |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aNeutropenia _xcomplications |
650 | 0 | 4 |
_aNorway _xepidemiology |
650 | 0 | 4 | _aRetrospective Studies |
650 | 0 | 4 | _aRisk Assessment |
650 | 0 | 4 | _aRisk Factors |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 | _aYoung Adult |
700 | 1 | _aGaustad, Peter | |
700 | 1 | _aMüller, Fredrik | |
700 | 1 | _aTorp Andersen, Cecilie | |
700 | 1 | _aBrunborg, Cathrine | |
700 | 1 | _aMylvaganam, Haima | |
700 | 1 | _aLeiva, Rafael Alexander | |
700 | 1 | _aBerdal, Jan Erik | |
700 | 1 | _aEgil Ranheim, Trond | |
700 | 1 | _aJohnsen, Bjørn Odd | |
700 | 1 | _aFalch, Birgit M | |
700 | 1 | _aGrimnes, Gro | |
700 | 1 | _aSkogen, Vegard | |
700 | 1 | _aHaarr, Elisebet | |
700 | 1 | _aSandmo Lyngøy, Anita | |
700 | 1 | _aWik Larssen, Kjersti | |
700 | 1 | _aHannula, Raisa | |
700 | 1 | _aÅsheim Hansen, Bjørn | |
700 | 1 | _aNordøy, Ingvild | |
773 | 0 |
_tInfectious diseases (London, England) _gvol. 51 _gno. 6 _gp. 425-434 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1080/23744235.2019.1595709 _zAvailable from publisher's website |
999 |
_c29613459 _d29613459 |